• No se han encontrado resultados

Migrañas que dan jaquecas

In document Boletín de Medicina y Traducción (página 95-99)

 Characterized pathologically as IRREVERSIBLE Chronic Injury of the Hepatic Parenchyma

 Include extensive fibrosis in association with the formation of Regenerative Nodules

Central Event leading to Hepatic Fibrosis: Cytokine-Mediated (tgf-B) Activation of the Hepatic Stellate Cells producing Fibrin Forming Type-1 Collagen

 Results from:

o Hepatocyte Necrosis

o Collapse of the supporting network with subsequent connective tissue deposition o Distortion of Vascular Bed, and Nodular Regeneration of remaining Liver Parenchyma I. ALCOHOLIC CIRRHOSIS

 Excessive chronic alcohol use can cause different types of Chronic Liver Disease: Alcoholic Fatty Liver, Alcoholic Hepatitis, and Alcoholic Cirrhosis

 Diagnosis requires an accurate history regarding amount and duration of alcohol consumption

 Laboratory Tests can be completely normal in patients with Early Compensated Alcoholic Cirrhosis

 In Advanced Liver Disease, patient may be:

o Anemic from either Chronic GI Blood Loss o Nutritional Deficiencies

o Hypersplenism related to Portal Hypertension

o Direct Suppressive Effect of Alcohol on the Bone Marrow II. CAUSES AND COMPLICATIONS OF CIRRHOSIS

III. LABORATORY FINDINGS IN CIRRHOSIS (from the Lecture)

 Liver Insufficiency:

o Decreased Albumin: < 3.8 g/dL o Prolonged PT (INR > 1.3) o Increased Bilirubin: > 1.5 mg/dL

 Portal Hypertension

o Decreased Platelet Count: < 175,000

 AST / ALT Ratio > 1

 Imaging (CT or UTZ) o Nodular Liver o Splenomegaly o Venocollaterals

 Liver Biopsy: NOT always necessary if:

o 1) Decompensated Cirrhosis (Variceal Hemorrhage, Ascites, etc) o 2) Liver/Spleen imaging diagnostic of Cirrhosis

LIVER ENZYMES:

AST / ALT > 2 Alcoholic Liver Disease AST / ALT < 1 Viral

Alk Phos > Liver Enzymes Cholestatic

COMPLICATIONS OF CIRRHOSIS:

Portal Hypertension (Gastroesophageal Varices, Portal Hypertensive Coagulopathy (Factor Deficiency, Fibrinoysis, Thrombocytopenia) Gastropathy, Splenomegaly, Hypersplenism, Ascites / SBP Bone Disease (Osteopenia, Osteoporosis, Osteomalacia)

Hepatorenal Syndrome (Type 1, Type 2) Hematologic Abnormalities (Anemia, Hemolysis, Neutropenia, Thrombocytopenia)

Hepatic Encephalopathy Malnutrition

Portopulmonary Hypertension Hepatopulmonary Syndrome

CAUSES OF CIRRHOSIS

Alcoholism Cardiac Cirrhosis

Chronic Viral Hepatitis (Hep-B, Hep-C) Inherited metabolic Liver Disease

Autoimmune Hepatitis - Hemochromatosis

Non-Alcoholic Steatohepatitis - Wilson’s Disease

Biliary Cirrhosis - A1-Antitrypsin Deficiency

Primary Biliary Cirrhosis - Cystic Fibrosis

Primary Sclerosing Cholangitis Cryptogenic Cirrhosis

Autoimmune Cholangiopathy

IV. SEVERITY OF LIVER DISEASE:

 Child Turcotte Pugh

 MELD Score

A. Child Pugh Criteria for Hepatic Functional Reserve

A B C

Serum Bilirubin (mg/dL) (umol/L)

< 2.0

< 34

2.0-3.0 34-51

> 3.0

> 51 Serum Albumin (g/dL)

(g/L) > 3.5

> 35 3.0-3.5

30-35 < 3.0

< 30 Prothrombin Time Seconds Prolonged

INR

0-4

< 1.7

4-6 1.7 – 2.3

> 6

> 2.3

Ascites None Easily controlled Poorly controlled

Neurologic Disorder None Minimal Advanced Coma

B. MELD Score

o Estimates the Risk of 3 month Mortality (higher the MELD score  likely to die in three months) o Three Laboratory Values used:

 Serum Total Bilirubin

 Serum Creatinine

 INR

6.4 + 9.8 x log(INR) + 11.2 x log(Cr) + 3.8 x log(Bilirubin)

V. HISTORY OF CHRONIC LIVER DISEASE

Chronic Liver Disease Compensated Cirrhosis Decompensated Cirrhosis Death

VI. COMPLICATIONS OF CIRRHOSIS

Portal Hypertension Liver Insufficiency

Variceal Hemorrhage Encephalopathy

SBP

Ascites Jaundice

Hepatorenal Syndrome Encephalopathy

Compensated VS Decompensated: Presence of Complications!

 Variceal Hemorrhage

 Ascites

 Encephalopathy

 Jaundice

VII. INVESTIGATING ASCITES

CONDITION GROSS APPEARANCE PROTEIN

(g/L)

SAAG (g/dL)

CELL COUNT OTHER TESTS

RBC,

>10,000u/L WBC, per uL Cirrhosis Straw colored or bile stained < 25 (95%) > 1.1 1% < 250 (90%)

Predominantly Mesothelial Neoplasm Straw colored, hemorrhagic,

mucinous, or chylous

> 25 (75%) < 1.1 20% > 1000 (50%) Variable Cell types

Cytology, cell block, peritoneal biopsy TB Peritonitis Clear, Turbid, Hemorrhagic,

Chylous

> 25 (50%) < 1.1 7% > 1000 (70%) Usually > 70% L

Peritoneal Biopsy, Stain and Culture for AFB Pyogenic

Peritonitis

Turbid or purulent If purulent,

> 25

< 1.1 Unusual Predominantly PMN Leukocytes

Positive Gram Stain, Culture

CHF Straw-colored Variable

(15-53)

Variable  Amylase in Ascitic Fluid & Serum A. SAAG: Serum to Ascites Albumin Gradient

o Serum Albumin [minus] Albumin in Ascitic Fluid (Gradient) o The gradient correlates DIRECTLY with Portal Pressure

1. If SAAG is > 1.1g/dL (or 11 g/L)

 Cause of Ascites is PORTAL HYPERTENSION with (97% Specificity):

 Cirrhosis

 Cardiac Ascites

 Budd Chiari Syndrome

 Portal Vein Thrombosis

 Veno-Occlusive Disease

 Fatty Liver of Pregnancy 2. If SAAG is < 1.1g/dL (or 11 g/L)

 Peritoneal Carcinomatosis

 Infection (Peritonitis, TB)

 Nephrotic Syndrome

 Pancreatic or Biliary Ascites B. Absolute WBC Count (PMN) > 250/mm3

o Infection

o When Mononuclear Cells are predominant: TB, Fungal C. RBC Count > 50,000/mm3 = Hemorrhagic Ascites

o Malignancy o TB

o Trauma D. Others:

Amylase Increased in Pancreatic Ascites

TAG Increased in Chylous Ascites

Cytology Positive in Malignancy Gram Stain or Culture Bacterial Infections pH < 7 Bacterial Infection E. Management of Ascites

o Removal of > 1 L at a time (Paracentesis) may lead to Hypovolemia, Shock

o

Unless 10grams Albumin is replaced IV for each 1 L Ascitic Fluid removed

Management of Ascites:

 Dietary Salt Restriction (2g Salt/day)

 Diuretic Therapy

 Paracntesis

 TIPS

Spontaneous Bacterial Peritonitis:

 Infectious complication of Portal HPN-Related Ascites

 Abdominal Pain & Distention, Fever, Decreased Bowel Sounds, Worsening of Hepatic Encephalopathy

Diagnosis is likely when Ascitic Fluid has >

250 neutrophils/u/L

VIII. HEPATIC ENCEPHALOPATHY: Grading System for Hepatic Encephalopathy:

Disorientation from time, amnesia, decreased inhibitions,

aroused, confused Disorientation for place, aggressive Asterixis, Hyperactive Reflexes,

Babinski’s Sign. Muscle Rigidity Slowing Triphasic Waves

4 Coma Nil Decrebrate Slowing Delta Waves

**NOTE: Asterixis is POSITIVE in Stage I, II, and III – but Negative on IV!

o There will be NO Asterixis when patients is already in COMA o First Manifestation is the Reversal of the Sleep-Wake Pattern

A. Pathogenesis (Most Important):

o SEVERE Hepatocellular Dysfunction and/or Intrahepatic & Extrahepatic Shunting of Portal Venous Blood into the Systemic Circulation BYPASSING the Liver (There is FAILURE to DETOXIFY the substances)

B. Common Precipitants of Hepatic Encephalopathy:

o Increased Nitrogen Load: Gastrointestinal Bleeding, Excess Dietary Protein, Azotemia, Constipation o Electrolyte and Metabolic Imbalance: Hypokalemia, Alkalosis, Hypoxia, Hyponatremia, Hypovolemia o Drugs: Narcotics, Tranquilizers, Sedatives, Diuretics

o Miscellaneous: Infection, Surgery, Superimposed Acute Liver Disease, Progressive Liver Disease, Portal-Systemic Shunts C. Aims of Treatment:

o 1) Eliminate or Treat the Precipitating Factors

o 2) Lower Blood Ammonia (and other Toxins): Decreases Absorption of Proteins and Nitrogenous Products from the Intestine D. Approach to the Patient with Hepatic Encephalopathy, BUN (Blood Urea Nitrogen)

Initial Evaluation:

Exclude other Causes of Disordered Mentation, Identify Precipitants and Correct Determine Electrolytes, BUN, Creatinine, NH3 (Optional), Glucose

Protein Restriction

Inadequate Response (?)

Laxative (eg. LACTULOSE 30-120mL, 1 to 4x daily until 4 stools/day)

Broad-Spectrum Antibiotics

(eg. Neomycin 500-1000mg qid; or Metronidazole 250mg tid)

Inadequate Response (?)

Consider Liver Transplantation

Portosystemic Encephalopathy is a serious complication of chronic liver disease and is broadly defined as an alteration in mental status & cognitive function occurring in the presence of liver failure.

Encephalopathy is more commonly seen in patients with chronic liver disease. Gut-derived neurotoxins are not removed by the liver because of vascular shunting and decreased hepatic mass get to the brain

& cause symptoms. Ammonia levels are typically elevated in patients with hepatic encephalopathy.

Treatment is multifactorial and includes management of the precipitating factors.

Sometimes hydration & correction of electrolyte imbalance is all that is necessary.

Mainstay of Treatment (in addition to correction of precipitating factors) is to use Lactulose, which result in Colonic Acidification. Catharsis ensues, contributing to the elimination of waste products in the gut. Goal: 2-3 Stools per day.

Treatment of Hepatic Encephalopathy (Washington)

 Treat Precipitating Factors

 Dietary Protein Restriction (Controversial)

Non-Absorbable Disaccharide (Lactulose, Lactitol)

 Neomycin

 Metronidazole (250mg PO q8h)

MANAGEMENT OF COMPLICATIONS

(Lecture)

In document Boletín de Medicina y Traducción (página 95-99)